Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a large number of broker notes this week.
Three broker buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Corporate Travel Management Ltd (ASX: CTD)
According to a note out of Ord Minnett, its analysts have upgraded this travel company's shares to a buy rating with an improved price target of $22.11. The broker made the move on valuation grounds after a recent pullback in the company's share price. It believes this has brought the company's shares down to an attractive level, especially given its positive growth outlook once the pandemic passes. The Corporate Travel Management share price is trading at $18.36 on Wednesday.
Healius Ltd (ASX: HLS)
A note out of UBS reveals that its analysts have upgraded this healthcare company's shares to a buy rating with a $4.40 price target. According to the note, the broker believes Healius is in a strong position to benefit from increased demand for COVID-19 testing. In addition to this, the broker notes that its strong form and a recent asset sale has brought back the possibility of a resumption in dividend payments and also potential share buybacks. The Healius share price is fetching $4.16 on Wednesday afternoon.
Volpara Health Technologies Ltd (ASX: VHT)
Analysts at Morgans have retained their add rating and lifted the price target on this healthcare technology company's shares to $1.92. This follows Volpara's announcement of the acquisition of breast cancer risk assessment company CRA Health for US$22 million. According to the note, Morgans believes the company has paid a fair price and expects the acquisition to broaden its reach. The Volpara share price is currently trading at $1.56.
